Moyamoya Disease Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The Moyamoya disease market was valued at USD 895.4 million in 2022, and a CAGR of 5.8% is expected during the forecast period. This diagnostic market includes cerebral angiograms, MRIs, CT scans, and PET scans. This disease is caused by a genetic disorder. Increased awareness of Moyamoya disease diagnostics is driving the growth of the market. It is a cerebrovascular disease that was first described in Japan. This name comes from the Japanese word “puff of smoke” and describes the appearance of tiny vessels that compensate for blockages. The increasing prevalence of this disease in Asian populations is driving the growth of the market.

Impact of Covid-19

COVID-19 had a significant impact on this market. Due to disruptions in the supply chain and stringent lockdown conditions all around the world, the market had to face a slowdown. Increasing public awareness about this disease and people being more knowledgeable about these diseases are driving the growth of the market significantly. Neurological diseases have become a challenge for the worldwide population these days, and increasing awareness about them is driving the growth of the market. Limited treatment options and the high cost of treatment were among the factors driving the growth of the market. During the pandemic, people's priorities shifted towards COVID-19. Increased emphasis on COVID-19 treatment worldwide was a hindrance to the market growth of other diseases.

Growth Drivers

Increasing public awareness about neurological disorders, increasing technological development in the medical diagnosis field, increasing research and developments, and increasing collaboration and partnerships are driving the growth of the market. Increasing government support worldwide and rising healthcare outcomes are driving the growth of the market significantly. Improved healthcare outcomes and rising awareness among people about disease diagnosis are driving the growth of the market.

Increasing growth in research and development activities is driving the growth of the market. Rising healthcare device modernization and technical breakthroughs are driving the growth of the market. Diagnostic imaging technologies, including MRIs and angiographies, have improved with time, leading to a more accurate and timely diagnosis of Moyamoya disease. Cooperation among pharmaceutical companies and academic institutions has driven the market towards success.

Segmentation

Drug Type

·         Blood Thinners

·         Calcium Channel Brokers

·         Anti-Seizure Medications

End-User

·         Hospitals

·         Pharmacies

·         Specialty Clinics

Treatment

·         Surgical

·         Non-Surgical

Diagnosis

·         Cerebral Angiogram

·         MRI

·         PET SCAN

·         CT-SCAN

·         Electroencephalography

·         Transcranial Doppler Ultrasound

·         MRA

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Moyamoya Disease Market Drug Type Segmentation

On the basis of drug type, the Moyamoya disease market is segmented into blood thinners, calcium channel brokers, and anti-seizure medications. The Moyamoya disease treatment landscape involved blood thinners, calcium channel brokers, and anti-seizure medications. Blood thinners are a very commonly used medicine worldwide and are used to reduce the risk of blood clots and strokes. Aspirin is the most commonly used blood thinner to prevent clot formation.

The use of blood thinners varies based on individual patients’ factors, and treatment decisions are typically made by a healthcare professional based on the patient’s specific condition and risk factors. Seizures do occur in individuals, along with Moyamoya disease. Medications like levetiracetam, carbamazepine, or phenytoin are often used to control and reduce the frequency of seizures, as well as the patient’s overall health and response to the medication. Consulting with a healthcare professional helps determine the most suitable antiseizure medicine for a patient.

Moyamoya Disease Diagnosis Market Segmentation

On the basis of disease diagnosis, the market is segmented into Cerebral angiogram, MRI, MRA, CT-Scan, PET SCAN, Transcranial Doppler Ultrasound, and Electroencephalography. MRI are primary imaging tools to visualize the blood vessels in the brain showing narrowing or blockage characteristics of Moyamoya. CT-Scan reveals change in the structure of brain, like areas of decreased blood flow, or signs of previous stroke. Cerebral angiography is an invasive procedure, involves injecting a contrast dye into blood vessels to obtain detailed images of the arteries in brain, providing precise information about blood flow, and vessel structure.

Transcranial Doppler Ultrasound is a non-invasive test evaluates blood flow in the brain by measuring sound waves reflecting off blood cells. It does indicate abnormalities in blood flow. Symptoms such as recurrent transient ischemic attacks, headaches or neurological deficits play a crucial role in diagnosis. A thorough evaluation by a neurologist is essential. The combination of these methods ensures the presence of Moyamoya disease in a patient. Increasing awareness about the neurological disorders is driving the growth in the market significantly.

Regional Outlook

On the basis of the regions, the Moyamoya disease market is segmented into 5 parts: Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. The Moyamoya disease market is dominating in the North American region and is expected to dominate during the forecast period. The development of novel and cutting-edge pharmaceuticals is driving the growth of the market. Increasing cases of obesity are increasing the number of patients suffering from the disease. Due to the busy and hectic lifestyles of people, the Asia-Pacific region is expected to remain the second-largest market after North America. Improving healthcare facilities in countries like Japan, China, and South Korea is driving the growth of the market significantly. The presence of key players in the United States and the European region is driving the growth of the market significantly.

The Moyamoya disease market in Europe saw ongoing research and attention, and increasing investment by the government in most of the European countries is driving the growth of the Moyamoya disease market. Germany, the United Kingdom, Spain, Italy, and France are the biggest markets in the region. Increasing growth in the pharmaceutical industry is driving the growth. The Middle East and Latin America markets are witnessing moderate growth during the forecast period due to poor healthcare expenditure, and infrastructure is responsible for the growth in the market. Growing awareness, research, and collaboration between global medical communities is driving the growth of the market significantly.

Key Players

·         Merck and co. Inc

·         Novartis AG

·         Sanofi Aventis Groupe

·         AbbVie Inc

·         Elli Lilly and Company

·         Pfizer

·         Valenta Pharmaceuticals company

·         Johnson and Johnson Services INC

·         Siemens Healthcare GmbH

·         Boston Scientific Corporation

·         Other Players